Objective: To compare the progression of erosions and joint space narrowing (JSN) in patients with early active rheumatoid arthritis (RA) using data obtained in the “Active-controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset” (ASPIRE) study.
Methods: This was a post hoc analysis of patients in ASPIRE who received placebo plus methotrexate (MTX) or infliximab (3 or 6 mg/kg) plus MTX. Radiographs of the hands (870 patients) and feet (871 patients) were obtained at baseline and week 54 and scored using the van der Heijde/Sharp method. In total, 7160 joints in the placebo plus MTX group and 18 908 joints in the combined infliximab plus MTX group were included in this analysis.
Results: At baseline, 83.4% of joints in the placebo plus MTX group had no radiographic damage, 8.5% had only erosions, 4.4% had only JSN and 3.7% had both. The distribution was similar in the infliximab plus MTX group. In the placebo plus MTX group, the majority of joints did not have development or progression of radiographic damage from baseline to week 54; among joints that did have development or progression of damage at week 54, erosions occurred more often than JSN. The same pattern was observed in the infliximab plus MTX group, although the proportions of joints with damage at week 54 were generally larger in the placebo plus MTX group. There was a tendency for joints with existing erosions or JSN to have progression of damage, rather than development of new damage.
Conclusions: Erosions were the predominant type of damage observed in both treatment groups. Erosions and JSN are related but partly independent processes.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This study was funded by Centocor, Horsham, Pennsylvania, USA and Schering-Plough, Kenilworth, New Jersey, USA.
Competing interests SX, JH and DB are employed by the sponsors of this study (Centocor). JSS has received research grants and/or honoraria from Abbott, Amgen, Astra-Zeneca, BMS, Centocor, Chugai, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB and Wyeth. DMvdH has received research grants and/or consulting fees from Abbott, Amgen, BMS, Centocor, Chugai, Novartis, Pfizer, Schering-Plough, UCB and Wyeth. DA has received honoraria from Abbott, Roche, Sanofi-Aventis, Schering-Plough and Wyeth. EWS has received research grants from Genentech, Amgen and Centocor and consulting fees from Genentech, Centocor and Bristol-Myers Squibb, as well as a fellowship training grant from Centocor. SX, JH and DB own stock in Johnson & Johnson, of which Centocor is a wholly owned subsidiary.
Ethics approval Ethics approval was obtained.